Considering the increased efforts to legalize marijuana in many states, greater public awareness of marijuana and its potential medicinal uses, and new research on cannabis and its constituents, it is essential that psychiatrists understand some of its proposed benefits—and fundamental risks.
Read More
President of the California Society of Addiction Medicine Itai Danovitch offers an overview of what psychiatrists should know about medical marijuana.
Read More
Several past studies have investigated a possible link between infections during pregnancy and psychiatric illness in the offspring. These studies may be biased, however, by poor recall or by a clinical, as opposed to serological, diagnosis of infection in the mother. A recent study attempted to overcome this bias by measuring influenza antibodies—a more precise manner of identifying influenza exposure—drawn from the mothers of bipolar offspring.
Read More
Does newspaper coverage of suicide promote copycat suicides? A recent retrospective study examined this question by comparing suicide clusters among teens to isolated suicides, and how local newspapers covered these events.
Read More
In mid-May, the FDA released a warning that eszopiclone (Lunesta) can cause next-day impairment when taken at the recommended target dose of 3 mg/day. As a result, the FDA has lowered the recommended starting dose to 1 mg/day.
Read More
A new drug is showing rapid, long-lasting results in early rodent studies, according to a paper presented by Jeffrey Talbot of Roseman University of Health Sciences at the annual meeting of the Federation of American Societies of Experimental Biology (FASEB) in April.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
